Methotrexate and Adalimumab Combination Efficacy in 4-year-old Child with Generalized Pustular Psoriasis: Case Study

Background. Generalized pustular psoriasis management in children is a topical issue due to limited use and efficacy of traditional immunodepressants, absence of registered genetically engineered biologic drugs. The description of biological drugs treatment results in children with pustular psoriasis within off-label indications is still relevant. Case description. 4-year-old child with generalized pustular psoriasis had limited methotrexate efficacy (cutaneous lesions exacerbations at a dose of 7.5 mg subcutaneously once per week), thus, genetically engineered biologic drug adalimumab was prescribed at a dose of 20 mg subcutaneously according to the recommended regimen. Positive dynamics was noted at follow-up scheduled examinations: complete regression of pustular rashes, laboratory blood values normalization, achievement of the PASI 100 at week 17. No side effects of adalimumab therapy were noted. Conclusion. Treatment with adalimumab (according to the recommended regimen) may be suggested in patients with generalized pustular psoriasis due to pathological process course severity, inefficacy of standard external therapy, antihistamine therapy, physiotherapy, traditional immunodepressants, including insufficient response to methotrexate, and in cases with no contraindications.

1. Choon SE, Navarini AA, Pinter A. Clinical Course and Characteristics of Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1): 21–29. doi: https://doi.org/10.1007/s40257-021-00654-z

2. Bachelez H. Pustular Psoriasis: The Dawn of a New Era. Acta Derm Venereol. 2020;100(3):adv00034. doi: https://doi.org/10.2340/00015555-3388

3. Esposito M, Antonetti P, Vagnozzi E, et al. Ixekizumab as a successful treatment in pediatric generalized pustular psoriasis. Ital J Pediatr. 2025;51(1):41. doi: https://doi.org/10.1186/s13052-024-01835-2

4. Bachelez H, Barker J, Burden AD, et al. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Rev Clin Immunol. 2022;18(10):1033–1047. doi: https://doi.org/10.1080/1744666X.2022.2116003

5. Miladi R, Janbakhsh A, Babazadeh A, et al. Pustular psoriasis flare-up in a patient with COVID-19. J Cosmet Dermatol. 2021;20(11): 3364–3368. doi: https://doi.org/10.1111/jocd.14508

6. Elmas ÖF, Demirbaş A, Kutlu Ö, et al. Psoriasis and COVID-19: A narrative review with treatment considerations. Dermatol Ther. 2020;33(6):e13858. doi: https://doi.org/10.1111/dth.13858

7. Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. Cytokine. 2015;73(2):342–350. doi: https://doi.org/10.1016/j.cyto.2014.12.014

8. Du Y, Yan Q, Chen M, et al. Efficacy of adalimumab in pediatric generalized pustular psoriasis: case series and literature review. J Dermatolog Treat. 2022;33(6):2862–2868. doi: https://doi.org/10.1080/09546634.2022.2089327

9. Jafarzadeh A, Behrangi E, Khosravi M, et al. Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors. Inflammopharmacology. 2025;33(4):1617–1672. doi: https://doi.org/10.1007/s10787-025-01675-4

10. Ivanov RA, Murashkin NN. Biological Therapy Survivability in Children with Psoriasis: Cohort Study. Voprosy sovremennoi pediatrii — Current Pediatrics. 2021;20(5):451–458. (In Russ). doi: https://doi.org/10.15690/vsp.v20i5.2323

11. Paller AS, Siegfried EC, Langley RG, et al. Long-Term Safety and Efficacy of Etanercept in Children and Adolescents with Plaque Psoriasis. J Am Acad Dermatol. 2016;74(2):280–287. doi: https://doi.org/10.1016/j.jaad.2015.09.056

12. Papp K, Thaçi D, Marcoux D, et al. Efficacy and Safety of Adalimumab Every Other Week versus Methotrexate Once Weekly in Children and Adolescents with Severe Chronic Plaque Psoriasis: a Randomised, DoubleBlind, Phase 3 Trial. Lancet. 2017;390(10089):40–49. doi: https://doi.org/10.1016/S0140-6736(17)31189-3

13. Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis. Expert Opin Drug Saf. 2020;19(8):969–980. doi: https://doi.org/10.1080/14740338.2020.1785427.